Logo 1.png
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
June 07, 2021 08:05 ET | Aeterna Zentaris Inc
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of...
Logo 1.png
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
June 03, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 13, 2021 08:05 ET | Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
Logo 1.png
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 05, 2021 16:35 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Logo 1.png
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
April 28, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:05 ET | Aeterna Zentaris Inc
– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...
Logo 1.png
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
March 15, 2021 08:05 ET | Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of intellectual property for the development of a...
Logo 1.png
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
March 11, 2021 08:05 ET | Aeterna Zentaris Inc
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which...
Logo 1.png
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
February 19, 2021 13:25 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET | Aeterna Zentaris Inc
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...